HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (75) Citing Articles via Google Scholar Google Scholar Articles by Höffken, G. Articles by Niederman, M. S. Search for Related Content PubMed PubMed Citation Articles by Höffken, G. Articles by Niederman, M. S.

Nosocomial Pneumonia^*

The Importance of a De-escalating Strategy for Antibiotic Treatment of Pneumonia in the ICU

^* From the Department of Pulmonology (Dr. Höffken), Universitätsklinikum Carl Gustav Carus, Dresden, Germany; and the Department of Medicine (Dr. Niederman), Winthrop-University Hospital, Mineola, NY.

Correspondence to: Michael S. Niederman, MD, FCCP, Professor of Medicine, SUNY at Stony Brook, Chairman, Department of Medicine, Winthrop-University Hospital, 222 Station Plaza North, Suite 400, Mineola, NY 11501; e-mail: mniederman{at}winthrop.org

Nosocomial pneumonia is the second most frequent nosocomial infection and represents the leading cause of death from infections that are acquired in the hospital. In the last decade, a large body of data has accumulated that points to the substantial impact of inadequate antibiotic treatment as a major risk factor for infection-attributed mortality in ventilator-associated pneumonia (VAP) patients. In most instances, high-risk pathogens (eg, highly resistant Gram-negative bacilli, such as Pseudomonas aeruginosa and Acinetobacter spp, as well as methicillin-resistant staphylococci) are the predominant microorganisms causing excess mortality. Among various risk factors for mortality from VAP, which include the severity of the underlying disease and the degree of functional physiologic impairment caused by the pulmonary infectious process, only inappropriate antibiotic therapy is directly amenable to modification by clinicians. Secondary modifications of an initially failing antibiotic regimen do not substantially improve the outcome for these critically ill patients. Therefore, the best approach for reducing infection-related mortality seems to be the initial institution of an adequate and broad-spectrum antibiotic regimen in severely ill patients, which should be modified in a de-escalating strategy when the results from microbiologic testing become available. To circumvent the inherent danger of the emergence of resistance in ICU patients, additional measures have to be implemented and tested in clinical trials to reduce antibiotic consumption, shorten the duration of antibiotic treatment, and reduce the selection pressure on the ICU flora. This latter goal could be met by new antibiotic strategies including scheduled changes of recommended empiric antibiotic regimens at fixed intervals on a rotating basis.

Key Words: de-escalating antibiotic strategy • ICU • nosocomial pneumonia • ventilator-associated pneumonia

This article has been cited by other articles:

				M. H. Kollef, L. E. Morrow, M. S. Niederman, K. V. Leeper, A. Anzueto, L. Benz-Scott, and F. J. Rodino Clinical Characteristics and Treatment Patterns Among Patients With Ventilator-Associated Pneumonia Chest, May 1, 2006; 129(5): 1210 - 1218. [Abstract] [Full Text] [PDF]

				G. W. Soo Hoo, Y. E. Wen, T. V. Nguyen, and M. B. Goetz Impact of Clinical Guidelines in the Management of Severe Hospital-Acquired Pneumonia Chest, October 1, 2005; 128(4): 2778 - 2787. [Abstract] [Full Text] [PDF]

				C. A. DeRyke, T. P. Lodise Jr., M. J. Rybak, and P. S. McKinnon Epidemiology, Treatment, and Outcomes of Nosocomial Bacteremic Staphylococcus aureus Pneumonia Chest, September 1, 2005; 128(3): 1414 - 1422. [Abstract] [Full Text] [PDF]

				R. T. Sadikot, T. S. Blackwell, J. W. Christman, and A. S. Prince Pathogen-Host Interactions in Pseudomonas aeruginosa Pneumonia Am. J. Respir. Crit. Care Med., June 1, 2005; 171(11): 1209 - 1223. [Abstract] [Full Text] [PDF]

				A. DiGiandomenico, J. Rao, and J. B. Goldberg Oral Vaccination of BALB/c Mice with Salmonella enterica Serovar Typhimurium Expressing Pseudomonas aeruginosa O Antigen Promotes Increased Survival in an Acute Fatal Pneumonia Model Infect. Immun., December 1, 2004; 72(12): 7012 - 7021. [Abstract] [Full Text] [PDF]

				J. Ogata, K. Minami, H. Miyamoto, T. Horishita, M. Ogawa, T. Sata, and H. Taniguchi Gargling with povidone-iodine reduces the transport of bacteria during oral intubation: [Le gargarisme avec un melange de povidone-iode reduit le transport bacterien pendant l'intubation orale] Can J Anesth, November 1, 2004; 51(9): 932 - 936. [Abstract] [Full Text] [PDF]

				P. Malacarne, C. Rossi, G. Bertolini, and for the GiViTI group Antibiotic usage in intensive care units: a pharmaco-epidemiological multicentre study J. Antimicrob. Chemother., July 1, 2004; 54(1): 221 - 224. [Abstract] [Full Text] [PDF]

				O. Leroy, T. d'Escrivan, H. Georges, and S. Alfandari Impact of Positive Microbiological Diagnosis on Management and Prognosis of Severe Community-Acquired Pneumonia Chest, September 1, 2003; 124(3): 1179 - 1180. [Full Text]